[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-371960-105":59,"doc-detail-371960-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","an-evidenced-based-review-and-commonsense-approach-to-prostate-cancer-screening-for-primary-care-physicians-volume-16-read-online-free","An Evidenced Based Review and CommonSense Approach to Prostate Cancer Screening for Primary Care Physicians - Volume 16 - read online free","","Prostate-specific antigen (PSA) screening reduces prostate cancer mortality but remains controversial because of overdiagnosis, overtreatment, and differing guideline recommendations. After a 2012 USPSTF grade D against PSA screening, PSA testing and biopsy rates declined and metastatic prostate cancer at diagnosis increased. The USPSTF later revised to grade C, emphasizing shared decision-making for men aged 55 to 69, while professional societies vary. This review summarizes evidence and contemporary tools for primary care physicians, advocating risk-stratified PSA initiation and follow-up to balance early detection with minimized harms.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/an-evidenced-based-review-and-commonsense-approach-to-prostate-cancer-screening-for-primary-care-physicians-volume-16-read-online-free/371960/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/an-evidenced-based-review-and-commonsense-approach-to-prostate-cancer-screening-for-primary-care-physicians-volume-16-read-online-free/371960.png","ImageObject",300,407,{"name":92,"@type":93},"OmBimo","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-24","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",12,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Why is PSA screening controversial for primary care clinicians?","Question",{"text":113,"@type":114},"PSA screening is debated due to concerns about overdiagnosis and overtreatment of indolent disease, as well as inconsistent guideline recommendations across organizations.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What changed after the 2012 USPSTF grade D recommendation?",{"text":118,"@type":114},"PSA testing and prostate biopsy rates declined, and the incidence of metastatic prostate cancer at diagnosis increased.",{"name":120,"@type":111,"acceptedAnswer":121},"How does the review suggest primary care physicians should implement PSA screening?",{"text":122,"@type":114},"It emphasizes an evidence-based, common-sense strategy using shared decision-making and contemporary diagnostic tools, advocating PSA initiation between ages 45 and 49 for men with average or elevated risk, with risk-stratified follow-up.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},371960,1790319529,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146},962090893581,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Journal of Primary Care & Community Health  \nAn Evidenced Based Review and CommonSense Approach to Prostate Cancer Screening for Primary Care Physicians, in an Era of Conflicting Guideline Recommendations and Debate  \nVolume 16: 1–11 © The Author(s) 2025 Article reuse guidelines:  \n[sagepub.com/journals-permissions](sagepub.com/journals-permissions)[ ](sagepub.com/journals-permissions)[DOI: 10.1177/21501319251401393](DOI: 10.1177/21501319251401393)[ ](DOI: 10.1177/21501319251401393)[journals.sagepub.com/home/jpc](journals.sagepub.com/home/jpc)  \nMahnoor Ashraf1*, Mouneeb Choudry 1*, Daniel Frendl 1, Gregory M. Garrison2, Chris Stephenson2, Nathaniel Miller2**, and Jack R. Andrews 1**  \nAbstract  \nProstate-specific antigen (PSA) screening has played a critical role in reducing prostate cancer mortality but remains controversial due to concerns regarding overdiagnosis, overtreatment, and inconsistent screening guidelines. In 2012, the United States Preventive Services Task Force (USPSTF) issued a grade D recommendation against PSA screening, leading toa national decline in PSA testing and prostate biopsy rates. This was followed by an increase in the incidence of metastatic prostate cancer at diagnosis. The USPSTF has since revised its recommendation to grade C, emphasizing shared decisionmaking for men aged 55 to 69 years. However, variability in screening recommendations across professional societies has resulted in clinical uncertainty, particularly for primary care physicians (PCPs), who frequently initiate PSA testing and urology referrals. This review provides an evidence-based overview of PSA screening tailored for the PCP. We performed a comprehensive literature review using Ovid MEDLINE, PubMed, Embase, and the Cochrane Library, including systematic reviews published between January 2020 and April 2025, and current guidelines from the American Urological Association (AUA), National Comprehensive Cancer Network (NCCN), European Association of Urology (EAU), and American Cancer Society (ACS). We summarize the evolving landscape of PSA screening and its integration with contemporary tools such as shared decision-making, multiparametric magnetic resonance imaging (mpMRI), and transperineally targeted biopsy. We advocate for initiating PSA screening between the ages of 45 and 49 in men with average or elevated risk, based on long-term evidence demonstrating the value of an early baseline PSA level and risk-stratified follow-up. This approach, coupled with improved diagnostic tools, can help PCPs navigate guideline variability and implement a rational, commonsense strategy to maximize early detection while minimizing harm.  \nKeywords  \nprostate-specific antigen, prostate cancer, primary care, urology, disease management  \nReceived: September 9, 2025; revised: November 11, 2025; accepted: November 12, 2025  \nIntroduction  \nProstate cancer is the most common non-cutaneous cancer among men in the United States and remains the second leading cause of cancer-related mortality. 1,2 Prostate-specific antigen (PSA) testing was introduced in the late 1980s and was widely adopted for the early detection of prostate cancer.  \nWhile PSA screening led to a substantial decline in prostate cancer mortality in the 1990s and early 2000s, its widespread  \n1 Mayo Clinic, Phoenix, AZ, USA 2Mayo Clinic, Rochester, MN, USA  \n*Co-First – Both authors contributed equally.  \n**Co-Senior – Both authors contributed equally.  \nCorresponding Author:  \nNathaniel Miller, Department of Family Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. [Email: miller.nathaniel@mayo.edu](Email: miller.nathaniel@mayo.edu)  \nCreative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License ([https://creativecommons.org/licenses/by-nc/4.0/](https://creativecommons.org/licenses/by-nc/4.0/)) which permits non-commercial use,  \nreproduction and distribution of the work witho","cbCaimrh6DOj2YYl","https://ap.wps.com/l/cbCaimrh6DOj2YYl","pdf",641362,11,"English","# Abstract\n# Introduction\n# PSA screening recommendations and evidence\n## USPSTF updates and guideline variability\n## Integration of shared decision-making and advanced diagnostics\n## Age to start, risk stratification, and follow-up strategy","[{\"question\":\"Why is PSA screening controversial for primary care clinicians?\",\"answer\":\"PSA screening is debated due to concerns about overdiagnosis and overtreatment of indolent disease, as well as inconsistent guideline recommendations across organizations.\"},{\"question\":\"What changed after the 2012 USPSTF grade D recommendation?\",\"answer\":\"PSA testing and prostate biopsy rates declined, and the incidence of metastatic prostate cancer at diagnosis increased.\"},{\"question\":\"How does the review suggest primary care physicians should implement PSA screening?\",\"answer\":\"It emphasizes an evidence-based, common-sense strategy using shared decision-making and contemporary diagnostic tools, advocating PSA initiation between ages 45 and 49 for men with average or elevated risk, with risk-stratified follow-up.\"}]","An Evidenced Based Review and CommonSense Approach to Prostate Cancer Screening for Primary Care Physicians - Volume 16 - read online free | PDF",1790193323,28]